Efficacy and Safety of Different Anticoagulation Regimens for Deep Vein Thrombosis in Real Clinical Practice
- 17 June 2024
- journal article
- research article
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (2)
Abstract
OBJECTIVE To evaluate the effectiveness and safety of different anticoagulation regimens for deep vein thrombosis in real clinical practice. MATERIAL AND METHODS We retrospectively analyzed the prospectively collected data on 462 patients with deep vein thrombosis. Patients in the main group received rivaroxaban, in the control group — warfarin. RESULTS The main group included 340 patients (179 men and 161 women aged 26-101 years (mean 61.5±15.6 years), the control group — 122 patients (60 men and 62 women aged 20—93 years (mean 62.0±16.8)). Recurrent venous thromboembolism under anticoagulation occurred in 6 (1.3%; 95% CI 0.6—2.8%) cases (1 (0.3%; 95% CI 0.1—1.7%) and 5 (4.1%; 95% CI 1.8—9.2%) cases, respectively, p=0.006). Bleeding occurred in 49 (10.6%; 95% CI 8.1—13.7%) patients (34 (10.0%; 95% CI 7.2—13.6%) and 15 (12.3%; 95% CI, 7.6—19.3%) patients, respectively, p=0.495). There were 2 (1.6%; 95% CI 0.5—5.8%) major bleeding events under warfarin therapy and no similar events in the main group. The Kaplan-Meier freedom from recurrent thrombosis and major bleeding was significantly in the main group. CONCLUSION Rivaroxaban for the treatment of deep vein thrombosis has made anticoagulation not only effective, but also safe regarding the risk of major bleeding.Keywords
This publication has 22 references indexed in Scilit:
- Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registryResearch and Practice in Thrombosis and Haemostasis, 2022
- Rivaroxaban in acute venous thromboembolism: UK prescribing experienceResearch and Practice in Thrombosis and Haemostasis, 2021
- Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studiesResearch and Practice in Thrombosis and Haemostasis, 2021
- Comparative effectiveness of oral anticoagulants in venous thromboembolism: GARFIELD-VTEThrombosis Research, 2020
- Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registryInternational Journal of Cardiology, 2018
- Real‐life Use of Anticoagulants in Venous Thromboembolism With a Focus on Patients With Exclusion Criteria for Direct Oral AnticoagulantsClinical Pharmacology & Therapeutics, 2017
- Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomesInternational Journal of Cardiology, 2017
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Evaluation of D-Dimer in the Diagnosis of Suspected Deep-Vein ThrombosisNew England Journal of Medicine, 2003